San Diego, CA - February 07, 2005
Cylene Pharmaceuticals, an oncology drug discovery and development company, today announced that it has relocated its corporate headquarters and R&D operations to 5820 Nancy Ridge Drive Suite 200, in the heart of San Diego's biotechnology center. The facility includes approximately 15,000 square feet of laboratory and office space.
"Cylene Pharmaceuticals' new headquarters will accommodate the company's growth needs in a facility designed specifically to accommodate state-of-the-art drug discovery and development activities," said William Rice, Ph.D., president and CEO of Cylene Pharmaceuticals. "We are at an exciting stage of growth as we continue to advance our therapeutic pipeline of quadruplex targeting agents into the clinic. The most advanced product candidate is CX-3543, our first-in-class compound directed against a unique DNA structure involved in the transcription and replication of a variety of oncogenes."
About Cylene Pharmaceuticals, Inc.
Cylene Pharmaceuticals, Inc. is a privately held pharmaceutical company dedicated to the discovery, development and commercialization of first-in-class small molecule drugs to treat life-threatening diseases, with a particular emphasis in oncology. Cylene's pipeline is led by CX-3543, a quadruplex targeting agent in late stage preclinical development. CX-3543 and other molecules in the pipeline originate from the company's proprietary platform, which directs small molecules at molecular targets that regulate the expression and replication of key oncogenes. More information can be found at www.cylenepharma.com.
Review Cylene's new contact information
